CA2366429A1 - Methods and compositions for regulating memory consolidation - Google Patents
Methods and compositions for regulating memory consolidation Download PDFInfo
- Publication number
- CA2366429A1 CA2366429A1 CA002366429A CA2366429A CA2366429A1 CA 2366429 A1 CA2366429 A1 CA 2366429A1 CA 002366429 A CA002366429 A CA 002366429A CA 2366429 A CA2366429 A CA 2366429A CA 2366429 A1 CA2366429 A1 CA 2366429A1
- Authority
- CA
- Canada
- Prior art keywords
- mammal
- memory consolidation
- hippocampus
- agent
- fornix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000005056 memory consolidation Effects 0.000 title claims abstract description 62
- 238000000034 method Methods 0.000 title claims abstract description 59
- 239000000203 mixture Substances 0.000 title description 6
- 230000001105 regulatory effect Effects 0.000 title 1
- 241000124008 Mammalia Species 0.000 claims abstract description 78
- 210000001320 hippocampus Anatomy 0.000 claims abstract description 41
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 30
- 230000006399 behavior Effects 0.000 claims abstract description 29
- 230000001404 mediated effect Effects 0.000 claims abstract description 21
- 230000011664 signaling Effects 0.000 claims abstract description 20
- 230000000694 effects Effects 0.000 claims abstract description 18
- 230000013016 learning Effects 0.000 claims abstract description 16
- 230000015654 memory Effects 0.000 claims abstract description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 44
- 241001465754 Metazoa Species 0.000 claims description 22
- 239000002858 neurotransmitter agent Substances 0.000 claims description 21
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 claims description 19
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 claims description 19
- 230000026731 phosphorylation Effects 0.000 claims description 13
- 238000006366 phosphorylation reaction Methods 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 12
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 11
- 239000000556 agonist Substances 0.000 claims description 10
- 239000005557 antagonist Substances 0.000 claims description 9
- 230000002708 enhancing effect Effects 0.000 claims description 9
- 230000003902 lesion Effects 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 230000028252 learning or memory Effects 0.000 claims description 7
- 210000002569 neuron Anatomy 0.000 claims description 6
- 230000005540 biological transmission Effects 0.000 claims description 5
- 230000003750 conditioning effect Effects 0.000 claims description 5
- 208000000044 Amnesia Diseases 0.000 claims description 4
- 208000031091 Amnestic disease Diseases 0.000 claims description 4
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 4
- 230000006986 amnesia Effects 0.000 claims description 4
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- 239000002853 nucleic acid probe Substances 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 3
- 230000001419 dependent effect Effects 0.000 claims description 2
- 230000000971 hippocampal effect Effects 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims 3
- 238000006243 chemical reaction Methods 0.000 claims 2
- 230000001537 neural effect Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 238000004611 spectroscopical analysis Methods 0.000 claims 2
- 108010054479 3',5'-Cyclic-AMP Phosphodiesterases Proteins 0.000 claims 1
- 102000001707 3',5'-Cyclic-AMP Phosphodiesterases Human genes 0.000 claims 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 108060000200 adenylate cyclase Proteins 0.000 claims 1
- 102000030621 adenylate cyclase Human genes 0.000 claims 1
- 230000003190 augmentative effect Effects 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 210000002932 cholinergic neuron Anatomy 0.000 claims 1
- 238000002591 computed tomography Methods 0.000 claims 1
- 238000011262 co‐therapy Methods 0.000 claims 1
- 230000003028 elevating effect Effects 0.000 claims 1
- 210000001222 gaba-ergic neuron Anatomy 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000002595 magnetic resonance imaging Methods 0.000 claims 1
- 230000006883 memory enhancing effect Effects 0.000 claims 1
- 230000007514 neuronal growth Effects 0.000 claims 1
- 230000006576 neuronal survival Effects 0.000 claims 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 1
- 238000002600 positron emission tomography Methods 0.000 claims 1
- 230000000862 serotonergic effect Effects 0.000 claims 1
- 230000008054 signal transmission Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Environmental Sciences (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biodiversity & Conservation Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Animal Husbandry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12430199P | 1999-03-12 | 1999-03-12 | |
| US60/124,301 | 1999-03-12 | ||
| PCT/US2000/006526 WO2000053738A2 (en) | 1999-03-12 | 2000-03-13 | Methods and compositions for regulating memory consolidation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2366429A1 true CA2366429A1 (en) | 2000-09-14 |
Family
ID=22414034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002366429A Abandoned CA2366429A1 (en) | 1999-03-12 | 2000-03-13 | Methods and compositions for regulating memory consolidation |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1161525A2 (ja) |
| JP (1) | JP2002541440A (ja) |
| AU (1) | AU3526400A (ja) |
| CA (1) | CA2366429A1 (ja) |
| IL (1) | IL145289A0 (ja) |
| WO (1) | WO2000053738A2 (ja) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2173369A2 (en) * | 2003-08-08 | 2010-04-14 | DSM IP Assets B.V. | Novel method for screening brain-active compounds |
| KR20110049801A (ko) * | 2008-07-18 | 2011-05-12 | 다트 뉴로사이언시즈, 엘엘씨 | 기억 물질의 평가를 위한 방법 및 시스템 |
| JP6448922B2 (ja) * | 2014-06-09 | 2019-01-09 | 国立研究開発法人産業技術総合研究所 | 非ヒト霊長類を用いた内包脳卒中モデル動物、およびその作成方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4004573A1 (de) * | 1989-02-17 | 1990-08-23 | Tanabe Seiyaku Co | Neues versuchstier und seine herstellung |
-
2000
- 2000-03-13 IL IL14528900A patent/IL145289A0/xx unknown
- 2000-03-13 CA CA002366429A patent/CA2366429A1/en not_active Abandoned
- 2000-03-13 EP EP00913904A patent/EP1161525A2/en not_active Withdrawn
- 2000-03-13 WO PCT/US2000/006526 patent/WO2000053738A2/en not_active Application Discontinuation
- 2000-03-13 AU AU35264/00A patent/AU3526400A/en not_active Abandoned
- 2000-03-13 JP JP2000603360A patent/JP2002541440A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002541440A (ja) | 2002-12-03 |
| WO2000053738A8 (en) | 2001-04-05 |
| WO2000053738A2 (en) | 2000-09-14 |
| EP1161525A2 (en) | 2001-12-12 |
| AU3526400A (en) | 2000-09-28 |
| IL145289A0 (en) | 2002-06-30 |
| WO2000053738A3 (en) | 2001-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dickson et al. | Rat transthyretin (prealbumin). Molecular cloning, nucleotide sequence, and gene expression in liver and brain. | |
| Mogil et al. | Identification of a sex-specific quantitative trait locus mediating nonopioid stress-induced analgesia in female mice | |
| Liao et al. | Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice. | |
| Suto et al. | Genetic analysis of non-insulin-dependent diabetes mellitus in KK and KK-Ay mice | |
| Wyrwicz et al. | Noninvasive observations of fluorinated anesthetics in rabbit brain by fluorine-19 nuclear magnetic resonance | |
| Rouleau et al. | Flanking markers bracket the neurofibromatosis type 2 (NF2) gene on chromosome 22. | |
| Aleman et al. | Association of a mutation in the ryanodine receptor 1 gene with equine malignant hyperthermia | |
| Cavanagh et al. | Bulldog dwarfism in Dexter cattle is caused by mutations in ACAN | |
| CH694204A5 (de) | Mit dem IGF-1 Rezeptor wechselwirkende Proteine (IIPs), Nukleinsaeuren, die fuer diese codieren, und deren Verwendungen | |
| Zoeller et al. | Cellular levels of messenger ribonucleic acids encoding vasoactive intestinal peptide and gastrin‐releasing peptide in neurons of the suprachiasmatic nucleus exhibit distinct 24‐hour rhythms | |
| Kasting et al. | Vasopressin may mediate febrile convulsions | |
| Mogil et al. | One or two genetic loci mediate high opiate analgesia in selectively bred mice | |
| Pant et al. | Comparative analyses of QTLs influencing obesity and metabolic phenotypes in pigs and humans | |
| Ferreira et al. | Forebrain structures specifically activated by conditioned taste aversion. | |
| Corcoran et al. | Pulmonary infiltration with eosinophils in 14 dogs | |
| Wang et al. | A versatile imaging platform with fluorescence and CT imaging capabilities that detects myeloperoxidase activity and inflammation at different scales | |
| Novelli et al. | Expression study of survival motor neuron gene in human fetal tissues | |
| Goldman et al. | Mapping of a putative genetic locus determining ethanol intake in the mouse | |
| Stylianou et al. | Microarray gene expression analysis of the Fob3b obesity QTL identifies positional candidate gene Sqle and perturbed cholesterol and glycolysis pathways | |
| CA2366429A1 (en) | Methods and compositions for regulating memory consolidation | |
| Dutil et al. | Further chromosomal mapping of a blood pressure QTL in Dahl rats on chromosome 2 using congenic strains | |
| Ziółkowska et al. | Regulation of the immediate-early genes arc and zif268 in a mouse operant model of cocaine seeking reinstatement | |
| Amenta et al. | Radioligand binding and autoradiographic analysis of dopamine receptors in the human heart | |
| England et al. | Romifidine as a premedicant to propofol induction and infusion anaesthesia in the dog | |
| Shelton et al. | Muscular dystrophy-dystroglycanopathy in a family of Labrador retrievers with a LARGE1 mutation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |